{"result": {"id": "636ba3a1-248d-4f81-bb36-507e9f149cc6", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Hypertension Research and Treatment Community\",\n    \"summary\": \"This community is centered around hypertension research and treatment, involving a wide range of researchers, medical journals, and clinical trials. Key entities include GRASSI G, JAMA NETW OPEN, and J AM COLL CARDIOL, among others, who are interconnected through collaborative research, publications, and clinical trials focused on hypertension and cardiovascular health. The community's work spans from understanding the physiological mechanisms of hypertension to developing and testing new treatments and management strategies.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the community's significant contributions to understanding and treating hypertension, a major global health issue.\",\n    \"findings\": [\n        {\n            \"summary\": \"GRASSI G's pivotal role in hypertension research\",\n            \"explanation\": \"GRASSI G is a central figure in the community, with research focusing on cardiovascular and metabolic health, particularly hypertension. Their work includes studies on omega-3 fatty acids, hypertension treatment strategies, and the sympathetic nervous system's role in hypertensive conditions. This research is crucial for advancing our understanding and management of hypertension. [Data: Entities (2682), Relationships (3237)]\"\n        },\n        {\n            \"summary\": \"JAMA NETW OPEN as a key platform for hypertension studies\",\n            \"explanation\": \"JAMA NETW OPEN serves as a vital platform for publishing high-quality, evidence-based research on hypertension treatments. It has published studies on nighttime masked uncontrolled hypertension and serves as a collaborative hub for researchers like FU X and CHALMERS J, among others. The journal's contributions are instrumental in disseminating cutting-edge research findings. [Data: Entities (2298), Relationships (2544, 2913, +more)]\"\n        },\n        {\n            \"summary\": \"The significance of J AM COLL CARDIOL in cardiovascular research\",\n            \"explanation\": \"J AM COLL CARDIOL is a leading journal in cardiovascular research, including hypertension. It has published groundbreaking studies, such as the phase 2b trial of the oral PCSK9 inhibitor MK-0616, and research on the risks associated with cigarette smoking and atherosclerotic diseases. The journal's publications are key resources for researchers and clinicians. [Data: Entities (2153), Relationships (2459, 2460, +more)]\"\n        },\n        {\n            \"summary\": \"Collaborative research on blood pressure meta-analyses\",\n            \"explanation\": \"Researchers like THOMOPOULOS C, PARATI G, and BAZOUKIS G have collaborated on meta-analyses of blood pressure-lowering randomized outcome trials. These collaborations highlight the community's effort to synthesize data from multiple studies to draw evidence-based conclusions on hypertension treatment. [Data: Relationships (2648, 2825)]\"\n        },\n        {\n            \"summary\": \"Advancements in hypertension treatment and management\",\n            \"explanation\": \"The community has made significant strides in developing and validating new treatments and management strategies for hypertension. This includes research on sacubitril/valsartan add-on therapy, the validation of wearable blood pressure monitors by companies like OMRON and HUAWEI, and the publication of clinical guidelines by organizations like the Canadian Cardiovascular Society. These advancements are crucial for improving patient care. [Data: Entities (2366, 2808), Relationships (2600, 2972, +more)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560525, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 720, "prompt_tokens": 8265, "total_tokens": 8985, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1600}, "prompt_cache_hit_tokens": 1600, "prompt_cache_miss_tokens": 6665}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n2682,GRASSI G,\"**GRASSI G** is a researcher with a primary focus on cardiovascular and metabolic health, particularly in the context of hypertension and related conditions. Their work spans multiple areas, including the study of **omega-3 fatty acids and their impact on coronary artery disease**, as well as investigations into **hypertension treatment strategies**. A significant portion of their research involves examining **sympathetic nerve traffic activation in essential hypertension** and the broader role of the **sympathetic nervous system in hypertensive conditions**. Additionally, GRASSI G has contributed to **meta-analyses of blood pressure-lowering randomized outcome trials** and has been associated with studies exploring **blood pressure targets in patients with type 2 diabetes**. Their multidisciplinary research underscores a strong emphasis on understanding and managing hypertension through both pharmacological and physiological approaches.\",6\n2298,JAMA NETW OPEN,\"**JAMA NETW OPEN** is a medical journal that publishes systematic reviews and network meta-analyses on a wide range of topics, including hypertension treatments. Among its published research is a study focusing on nighttime masked uncontrolled hypertension and its effects. The journal serves as a platform for high-quality, evidence-based research in the medical field, contributing to advancements in clinical understanding and patient care.\",58\n2312,FU X,\"A researcher involved in a study on nighttime masked uncontrolled hypertension\"\"\",3\n2808,CAN J CARDIOL,\"The *Canadian Journal of Cardiology (CAN J CARDIOL)* is a peer-reviewed medical journal dedicated to publishing research in the field of cardiology, with a particular focus on hypertension. It has featured studies on various topics, including hypertension resulting from antiangiogenic therapy. Additionally, the journal is recognized for publishing authoritative clinical guidelines, such as the *2021 Canadian Cardiovascular Society guidelines*, which serve as a key reference for cardiovascular practitioners in Canada and beyond. The journal serves as an important platform for disseminating cutting-edge research and evidence-based recommendations in cardiology.\",3\n2773,CHALMERS J,\"A researcher involved in studies on hypertension treatments, particularly indapamide and perindopril>\",1\n2774,MOURAD JJ,A researcher contributing to studies on hypertension treatments>,1\n2775,BRZOZOWSKA-VILLATTE R,A researcher involved in hypertension treatment studies>,1\n2776,ISHANI A,A researcher comparing chlorthalidone and hydrochlorothiazide for hypertension treatment>,1\n2777,LEATHERMAN SM,A researcher contributing to hypertension treatment research>,1\n2778,KUYPER LM,A researcher comparing atenolol and non-atenolol β-blockers for hypertension>,1\n2779,KHAN NA,A researcher involved in meta-analyses of hypertension treatments>,1\n2780,DEARY AJ,A researcher conducting double-blind studies on antihypertensive drugs>,1\n2781,SCHUMANN AL,A researcher involved in hypertension drug comparison studies>,1\n2782,MURFET H,A researcher contributing to antihypertensive drug trials>,1\n2783,LU X,A researcher contributing to hypertension management studies>,1\n2784,MARK A,A researcher investigating hypertension and the sympathetic nervous system>,1\n2786,STEFAN MS,A researcher studying β-blocker therapy outcomes in hypertension>,1\n2787,ROTHBERG MB,A researcher involved in studies on hypertension and cardiovascular outcomes>,1\n2788,PRIYA A,A researcher contributing to hypertension and lung disease studies>,1\n2789,LEVIN ER,A researcher studying natriuretic peptides in hypertension>,1\n2790,GARDNER DG,A researcher involved in natriuretic peptide studies>,1\n2791,SAMSONET WK,A researcher contributing to natriuretic peptide research>,1\n2792,ARENDSE LB,A researcher investigating novel hypertension therapies>,1\n2793,DANSER A,A researcher studying the renin-angiotensin system in hypertension>,1\n2794,POGLITSCH M,A researcher involved in hypertension and heart failure studies>,1\n2796,YAN J,A researcher contributing to hypertension treatment studies>,1\n2797,GU J,A researcher studying pharmacokinetics of LCZ696 for hypertension>,1\n2798,NOE A,A researcher involved in hypertension drug development>,1\n2799,CHANDRA P,A researcher contributing to hypertension treatment research>,1\n2800,LIN DS,A researcher studying angiotensin receptor neprilysin inhibitors for hypertension>,1\n2802,GENG Q,A researcher studying LCZ696 effects on blood pressure>,1\n2803,YAN R,A researcher involved in hypertension meta-analyses>,1\n2804,YUKISADA K,A researcher involved in hypertension drug trials>,1\n2805,SIBULO A JR,A researcher contributing to hypertension treatment research>,1\n2809,INT J CLIN PRACT,A medical journal publishing clinical studies on hypertension management>,1\n2811,THORAX,A medical journal publishing studies on lung diseases and associated hypertension conditions>,1\n2812,PHARMACOL REV,A journal publishing reviews on pharmacological treatments for hypertension>,1\n2813,CARDIOLOGY,\"**CARDIOLOGY** is a journal dedicated to publishing research on cardiovascular diseases, with a particular focus on hypertension. In 2020, it published a meta-analysis of randomized controlled trials examining blood pressure in patients with hypertension. The journal serves as a key resource for advancing knowledge and evidence-based practices in the field of cardiology.\",1\n2814,CHINESE HOSPITAL PHARMACY JOURNAL,A journal publishing expert consensus on hypertension treatments in China>,1\n2815,J CLIN PHARMACOL,A journal publishing pharmacokinetic and pharmacodynamic studies on hypertension drugs>,1\n2153,J AM COLL CARDIOL,\"**J AM COLL CARDIOL (Journal of the American College of Cardiology)** is a leading medical journal dedicated to publishing high-quality research on cardiovascular diseases and related conditions. It covers a broad spectrum of topics in cardiology, including the risks associated with cigarette smoking and atherosclerotic diseases, hypertension, and long-term cardiovascular risks linked to stage 1 hypertension. The journal also explores cardiovascular outcomes following hypertensive disorders of pregnancy. Additionally, **J AM COLL CARDIOL** serves as a platform for groundbreaking clinical trials, such as the phase 2b trial of the oral PCSK9 inhibitor MK-0616. Recognized for its influential contributions to the field, the journal remains a key resource for researchers and clinicians in cardiovascular medicine.\",9\n2183,DING N,\"A researcher involved in a study on cigarette smoking and the risk of atherosclerotic diseases>\nResearcher who studied cigarette smoking and atherosclerotic diseases>\",1\n2184,SANG YY,\"A researcher involved in a study on cigarette smoking and the risk of atherosclerotic diseases>\nResearcher who studied cigarette smoking and atherosclerotic diseases>\",1\n2185,CHEN JS,\"CHEN JS is a researcher whose work spans multiple areas of cardiovascular and public health research. They have conducted studies on the relationship between cigarette smoking and the risk of atherosclerotic diseases, contributing to the understanding of how smoking impacts vascular health. Additionally, CHEN JS has investigated the effects of antihypertensive drugs on left ventricular hypertrophy, exploring pharmacological interventions for heart-related conditions. Their research demonstrates a focus on both behavioral risk factors (such as smoking) and clinical treatments (such as antihypertensive therapies) in the context of cardiovascular diseases.\",1\n4696,BALLANTYNE CM,\"Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\"\"\",1\n4697,BANKA P,\"Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\"\"\",1\n4698,MENDEZ G,\"Researcher involved in the phase 2b trial of oral PCSK9 inhibitor MK-0616\"\"\",1\n4716,PCSK9 INHIBITOR MK-0616,\"Oral medication evaluated in a phase 2b randomized trial\"\"\",1\n2463,THOMOPOULOS C,\"THOMOPOULOS C is a researcher specializing in the study of hypertension treatment and blood pressure-lowering therapies. Their work focuses on analyzing the effects of various blood pressure-lowering treatments, including conducting meta-analyses of randomized outcome trials in this field. THOMOPOULOS C's research contributes to a deeper understanding of how different interventions impact blood pressure and their broader implications for patient outcomes. Their involvement in meta-analyses highlights their expertise in synthesizing data from multiple studies to draw evidence-based conclusions.\",5\n2379,PARATI G,\"**PARATI G** is a researcher specializing in hypertension and cardiovascular outcomes, with a focus on blood pressure variability and its implications for cardiovascular homeostasis and diseases. They have contributed to the field as a co-author of European Society of Hypertension consensus statements and have conducted research analyzing the effects of blood pressure lowering. Their work underscores their expertise in hypertension management and cardiovascular health.\",3\n2681,BAZOUKIS G,\"**BAZOUKIS G** is a researcher primarily involved in studies related to hypertension treatment. Their work includes participation in a meta-analysis of blood pressure-lowering randomized outcome trials, contributing to the broader understanding of effective hypertension management strategies. This aligns with their focus on cardiovascular research and evidence-based approaches to treating high blood pressure.\",2\n2747,WANGJG,\"**WANGJG** is a researcher who has contributed to multiple studies in the field of cardiovascular medicine, with a focus on hypertension and related treatments. Notably, WANGJG participated in a study investigating the efficacy and safety of sacubitril/valsartan as an add-on therapy to amlodipine in Asian patients with systolic hypertension. Additionally, WANGJG has contributed to systematic reviews and meta-analyses examining the effects of angiotensin-receptor blockers (ARBs), further demonstrating expertise in antihypertensive therapies. These contributions highlight WANGJG's involvement in advancing research on cardiovascular treatments, particularly in the context of hypertension management.\",5\n2770,J CLIN HYPERTENS,\"**J CLIN HYPERTENS (Journal of Clinical Hypertension)** is a medical journal dedicated to clinical hypertension research, treatments, and clinical practice. It covers a broad range of topics related to hypertension, including telemonitoring studies, pharmacological interventions, and comorbid conditions. For instance, the journal published a 2022 study on the efficacy of angiotensin receptor neprilysin inhibitors in Asian patients with refractory hypertension, as well as Prisant LM's research on the relationship between hyperthyroidism and hypertension. The journal serves as a key resource for advancing knowledge in hypertension management, integrating both innovative and established therapeutic approaches.\",3\n2368,STERGIOU GS,\"STERGIOU GS is a prominent researcher known for his significant contributions to the field of hypertension and blood pressure monitoring. He has been a key figure involved in the development of the European Society of Hypertension guidelines on blood pressure monitoring, underscoring his expertise in the area. Additionally, Stergiou GS has actively advocated for the importance of home blood pressure monitoring, emphasizing its role in improving patient care and management of hypertension. His work reflects a strong commitment to advancing clinical practices and guidelines in cardiovascular health.\",4\n2464,ZANCHETTI A,\"ZANCHETTI A is a researcher primarily focused on the study of antihypertensive drugs, with a specialization in meta-analyses related to their effects. Their work involves analyzing the blood pressure-lowering properties of these medications, contributing to a deeper understanding of their efficacy and clinical applications. Through their research, ZANCHETTI A plays a key role in advancing knowledge in the field of hypertension treatment.\",2\n2817,SIBULOAJR,SibuloAJr is a researcher who contributed to a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension,2\n2366,HUAWEI,\"Huawei developed a wrist blood pressure monitor validated for use in Chinese adults\"\"\",2\n2381,ZHANG W,\"**ZHANG W** is a researcher specializing in hypertension and related cardiovascular and renal conditions. Their work includes involvement in clinical trials focused on hypertension drug development, chronic kidney disease, and intensive blood-pressure control strategies, particularly in older patients. Additionally, ZHANG W has contributed to the validation of medical devices, such as Huawei's blood pressure monitor, demonstrating expertise in both clinical research and medical technology assessment. Their research spans therapeutic interventions, patient-specific treatment approaches, and diagnostic tool verification, highlighting a multidisciplinary focus on improving hypertension management.\",4\n2748,ZHANGM,\"ZhangM is a researcher involved in studies comparing the efficacy of angiotensin-receptor blockers.\"\"\",1\n2749,FENGYQ,\"FengYQ is a researcher who co-authored meta-analyses on angiotensin-receptor blockers.\"\"\",1\n2476,CUSHMAN WC,\"**CUSHMAN WC** is a researcher or author primarily associated with studies on hypertension, blood pressure control, and cardiovascular events. Their work has focused on diverse North American settings, examining the effects of intensive blood pressure management, particularly in populations with type 2 diabetes mellitus. Cushman WC has been involved with the **ACCORD Study Group**, which investigates the impact of rigorous blood-pressure control in diabetic patients. Their research contributions span both clinical and epidemiological aspects of cardiovascular health, emphasizing the relationship between hypertension and broader cardiovascular outcomes.\",3\n3538,ALLHAT,The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a clinical trial on blood pressure control>,3\n2296,AM HEART J,\"A medical journal that published research on cardiovascular incidence related to diabetes and metabolic syndrome\"\"\",1\n2311,LIU J,LIU J is a researcher with expertise in hypertension management and cardiovascular risk epidemiology. They have contributed to expert consensus guidelines on hypertension management and have been involved in studies focusing on cardiovascular risk factors and epidemiological research. Their work spans both clinical recommendations and population-based research in the field of cardiovascular health.,4\n2327,GRUNDY SM,\"GRUNDY SM is a researcher known for their work in the field of cardiovascular health, particularly in studies related to diabetes and metabolic syndrome. They have contributed to research examining the incidence of cardiovascular conditions in these contexts. Additionally, GRUNDY SM has played a role in developing clinical guidelines, serving as a co-author for recommendations on the management of hyperlipidemia. Their expertise spans both research and practical applications in metabolic and cardiovascular health.\",1\n2328,WANG W,\"A researcher involved in a study on cardiovascular incidence related to diabetes and metabolic syndrome\"\"\",1\n2380,KOLLIAS A,\"Co-author of European Society of Hypertension consensus statements\"\"\",1\n2472,ACCORD STUDY GROUP,A research group that studied the effects of intensive blood-pressure control in type 2 diabetes mellitus,2\n3472,SHI W,\"A researcher involved in studies on hypertension and chronic kidney disease\"\"\",1\n3473,LIU Z,\"A researcher involved in studies on hypertension and chronic kidney disease\"\"\",1\n3195,CUTLER JA,\"Cutler JA is a researcher primarily focused on studies related to hypertension, cardiovascular disease, and blood pressure control. Their work is associated with diverse North American settings, where they contribute as an author or investigator in research aimed at understanding and managing these health conditions. Their expertise spans both clinical and epidemiological aspects of cardiovascular health.\",2\n4573,PEARSON GJ,\"Co-author of the 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia\"\"\",2\n4602,CANADIAN CARDIOVASCULAR SOCIETY,\"Organization that published the 2021 guidelines for the management of dyslipidemia\"\"\",3\n2331,REN H,\"A researcher involved in a study on nighttime masked uncontrolled hypertension\"\"\",1\n2332,XIE J,\"A researcher involved in a study on nighttime masked uncontrolled hypertension\"\"\",1\n2365,OMRON,\"Omron manufactures wearable blood pressure monitors validated by ANSI/AAMI/ISO standards\"\"\",2\n2816,YUKISADAK,YukisadaK is a researcher who contributed to a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension,2\n3194,MACMAHON SW,MacMahon SW is a researcher who contributed to studies on hypertension and cardiovascular disease,2\n3209,PROG CARDIOVASC DIS,,2\n3529,FORD CE,Ford CE is a researcher or author associated with studies on blood pressure control in diverse North American settings>,1\n3623,PRISANT LM,\"Prisant LM is an author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\"\"\",3\n3624,GUJRAL JS,\"Gujral JS is a co-author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\"\"\",1\n3625,MULLOY AL,\"Mulloy AL is a co-author of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension\"\"\",1\n3710,ITALIAN SOCIETY OF HYPERTENSION (SIIA),\"The Italian Society of Hypertension (SIIA) is a professional organization that published a consensus document on sleep disorders, high blood pressure, and cardiovascular diseases>\",3\n3714,DEL PINTO R,\"Del Pinto R is a researcher who co-authored a consensus document on sleep disorders, high blood pressure, and cardiovascular diseases>\",1\n3724,FERRI C,Ferri C is a researcher who contributed to a consensus document on sleep disorders and hypertension>,1\n4574,THANASSOULIS G,\"Co-author of the 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia\"\"\",1\n4575,ANDERSON TJ,\"Co-author of the 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia\"\"\",1\n2314,QI Y,\"A researcher involved in a study on long-term cardiovascular risk associated with stage 1 hypertension\"\"\",2\n2335,HAN X,\"A researcher involved in a study on long-term cardiovascular risk associated with stage 1 hypertension\"\"\",1\n2373,ANSI/AAMI/ISO,\"Standards organization that validated Omron's blood pressure monitors\"\"\",1\n2477,EVANS GW,\"Researcher involved in the ACCORD Study Group, studying effects of intensive blood-pressure control in type 2 diabetes mellitus\",1\n4576,DEMBOWSKI E,\"Co-author of guidelines for the management of hyperlipidemia\"\"\",1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n3237,GRASSI G,HYPERTENSION,Grassi G published research in Hypertension,189\n2544,JAMA NETW OPEN,FU X,Fu X co-authored a study published in JAMA Netw Open,61\n2959,JAMA NETW OPEN,CAN J CARDIOL,Both publish studies on hypertension and cardiovascular outcomes,61\n2913,JAMA NETW OPEN,CHALMERS J,Chalmers J contributed to research published in JAMA Netw Open,59\n2914,JAMA NETW OPEN,MOURAD JJ,Mourad JJ contributed to research published in JAMA Netw Open,59\n2915,JAMA NETW OPEN,BRZOZOWSKA-VILLATTE R,Brzozowska-Villatte R contributed to research published in JAMA Netw Open,59\n2919,JAMA NETW OPEN,ISHANI A,Ishani A contributed to research published in JAMA Netw Open,59\n2921,JAMA NETW OPEN,LEATHERMAN SM,Leatherman SM contributed to research published in JAMA Netw Open,59\n2922,JAMA NETW OPEN,KUYPER LM,Kuyper LM contributed to research published in JAMA Netw Open,59\n2923,JAMA NETW OPEN,KHAN NA,Khan NA contributed to research published in JAMA Netw Open,59\n2924,JAMA NETW OPEN,DEARY AJ,Deary AJ contributed to research published in JAMA Netw Open,59\n2925,JAMA NETW OPEN,SCHUMANN AL,Schumann AL contributed to research published in JAMA Netw Open,59\n2926,JAMA NETW OPEN,MURFET H,Murfet H contributed to research published in JAMA Netw Open,59\n2928,JAMA NETW OPEN,LU X,Lu X contributed to research published in JAMA Netw Open,59\n2931,JAMA NETW OPEN,MARK A,Mark A contributed to research published in JAMA Netw Open,59\n2933,JAMA NETW OPEN,STEFAN MS,Stefan MS contributed to research published in JAMA Netw Open,59\n2934,JAMA NETW OPEN,ROTHBERG MB,Rothberg MB contributed to research published in JAMA Netw Open,59\n2935,JAMA NETW OPEN,PRIYA A,Priya A contributed to research published in JAMA Netw Open,59\n2936,JAMA NETW OPEN,LEVIN ER,Levin ER contributed to research published in JAMA Netw Open,59\n2937,JAMA NETW OPEN,GARDNER DG,Gardner DG contributed to research published in JAMA Netw Open,59\n2938,JAMA NETW OPEN,SAMSONET WK,Samsonet WK contributed to research published in JAMA Netw Open,59\n2939,JAMA NETW OPEN,ARENDSE LB,Arendse LB contributed to research published in JAMA Netw Open,59\n2940,JAMA NETW OPEN,DANSER A,Danser A contributed to research published in JAMA Netw Open,59\n2941,JAMA NETW OPEN,POGLITSCH M,Poglitsch M contributed to research published in JAMA Netw Open,59\n2944,JAMA NETW OPEN,YAN J,Yan J contributed to research published in JAMA Netw Open,59\n2945,JAMA NETW OPEN,GU J,Gu J contributed to research published in JAMA Netw Open,59\n2946,JAMA NETW OPEN,NOE A,Noe A contributed to research published in JAMA Netw Open,59\n2947,JAMA NETW OPEN,CHANDRA P,Chandra P contributed to research published in JAMA Netw Open,59\n2948,JAMA NETW OPEN,LIN DS,Lin DS contributed to research published in JAMA Netw Open,59\n2951,JAMA NETW OPEN,GENG Q,Geng Q contributed to research published in JAMA Netw Open,59\n2952,JAMA NETW OPEN,YAN R,Yan R contributed to research published in JAMA Netw Open,59\n2955,JAMA NETW OPEN,YUKISADA K,Yukisada K contributed to research published in JAMA Netw Open,59\n2956,JAMA NETW OPEN,SIBULO A JR,Sibulo A Jr contributed to research published in JAMA Netw Open,59\n2960,JAMA NETW OPEN,INT J CLIN PRACT,Both journals publish clinical studies on hypertension management,59\n2962,JAMA NETW OPEN,THORAX,Both publish studies on hypertension-related conditions,59\n2963,JAMA NETW OPEN,PHARMACOL REV,Both publish reviews on hypertension treatments,59\n2967,JAMA NETW OPEN,CARDIOLOGY,Both publish studies on hypertension and cardiovascular outcomes,59\n2968,JAMA NETW OPEN,CHINESE HOSPITAL PHARMACY JOURNAL,Both publish expert consensus on hypertension treatments,59\n2969,JAMA NETW OPEN,J CLIN PHARMACOL,Both publish pharmacokinetic studies on hypertension drugs,59\n2459,J AM COLL CARDIOL,DING N,\"Ding N published smoking research in J Am Coll Cardiol\nDing N's research on smoking and atherosclerotic diseases was published in J Am Coll Cardiol\",10\n2460,J AM COLL CARDIOL,SANG YY,\"Sang YY's research on smoking and atherosclerotic diseases was published in J Am Coll Cardiol\nSang YY published smoking research in J Am Coll Cardiol\",10\n2461,J AM COLL CARDIOL,CHEN JS,\"Chen JS's research on smoking and atherosclerotic diseases was published in J Am Coll Cardiol\nChen JS published smoking research in J Am Coll Cardiol\",10\n4532,BALLANTYNE CM,J AM COLL CARDIOL,Ballantyne CM was a researcher in a study published in J Am Coll Cardiol,10\n4533,BANKA P,J AM COLL CARDIOL,Banka P was a researcher in a study published in J Am Coll Cardiol,10\n4534,MENDEZ G,J AM COLL CARDIOL,Mendez G was a researcher in a study published in J Am Coll Cardiol,10\n4535,J AM COLL CARDIOL,PCSK9 INHIBITOR MK-0616,Trial of MK-0616 was published in JACC,10\n2648,THOMOPOULOS C,PARATI G,Co-authors of a blood pressure meta-analysis,8\n2825,BAZOUKIS G,GRASSI G,Both researchers collaborated on a meta-analysis of blood pressure lowering randomized outcome trials.,8\n2893,WANGJG,J CLIN HYPERTENS,WangJG's meta-analysis on angiotensin-receptor blockers was published in Journal of Clinical Hypertension,8\n2605,STERGIOU GS,PARATI G,Co-authors of European Society of Hypertension statements,7\n2649,THOMOPOULOS C,ZANCHETTI A,Co-authors of a blood pressure meta-analysis,7\n2972,WANGJG,SIBULOAJR,WangJG and SibuloAJr are co-authors of a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension,7\n2600,HUAWEI,ZHANG W,Researcher who validated Huawei's blood pressure monitor,6\n2891,WANGJG,ZHANGM,WangJG and ZhangM co-authored meta-analyses on angiotensin-receptor blockers.,6\n2892,WANGJG,FENGYQ,WangJG and FengYQ collaborated on systematic reviews of cardiovascular treatments.,6\n3579,CUSHMAN WC,ALLHAT,Cushman WC is associated with the ALLHAT clinical trial,6\n2542,AM HEART J,LIU J,Liu J co-authored a study published in Am Heart J,5\n2561,LIU J,GRUNDY SM,Liu J and Grundy SM co-authored a study on cardiovascular risk,5\n2562,LIU J,WANG W,Liu J and Wang W co-authored a study on cardiovascular risk,5\n2606,STERGIOU GS,KOLLIAS A,Co-authors of European Society of Hypertension statements,5\n2655,ACCORD STUDY GROUP,CUSHMAN WC,Cushman WC is a researcher involved in the ACCORD Study Group,5\n3533,ZHANG W,SHI W,Co-authors of research on hypertension and chronic kidney disease,5\n3534,ZHANG W,LIU Z,Co-authors of research on hypertension and chronic kidney disease,5\n3581,CUTLER JA,ALLHAT,Cutler JA is associated with the ALLHAT clinical trial,5\n4448,PEARSON GJ,CANADIAN CARDIOVASCULAR SOCIETY,Pearson GJ co-authored guidelines published by the Canadian Cardiovascular Society,5\n2565,FU X,REN H,Fu X and Ren H co-authored a study on nighttime hypertension,4\n2566,FU X,XIE J,Fu X and Xie J co-authored a study on nighttime hypertension,4\n2598,OMRON,HUAWEI,Both companies manufacture validated wearable blood pressure monitors,4\n2973,YUKISADAK,SIBULOAJR,YukisadaK and SibuloAJr are co-authors of a study on the efficacy and safety of sacubitril/valsartan add-on to amlodipine in Asian patients with systolic hypertension,4\n3352,MACMAHON SW,CUTLER JA,MacMahon SW and Cutler JA co-authored research on hypertension and cardiovascular disease,4\n3353,MACMAHON SW,PROG CARDIOVASC DIS,Prog Cardiovasc Dis published research by MacMahon SW on hypertension treatment effects,4\n3580,FORD CE,ALLHAT,Ford CE is associated with the ALLHAT clinical trial,4\n3669,PRISANT LM,GUJRAL JS,Both are co-authors of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension,4\n3670,PRISANT LM,MULLOY AL,Both are co-authors of a study on hyperthyroidism as a secondary cause of isolated systolic hypertension,4\n3738,ITALIAN SOCIETY OF HYPERTENSION (SIIA),DEL PINTO R,Del Pinto R co-authored a consensus document published by the Italian Society of Hypertension,4\n3740,ITALIAN SOCIETY OF HYPERTENSION (SIIA),FERRI C,Ferri C contributed to a consensus document by the Italian Society of Hypertension,4\n4450,THANASSOULIS G,CANADIAN CARDIOVASCULAR SOCIETY,Thanassoulis G co-authored guidelines published by the Canadian Cardiovascular Society,4\n4451,ANDERSON TJ,CANADIAN CARDIOVASCULAR SOCIETY,Anderson TJ co-authored guidelines published by the Canadian Cardiovascular Society,4\n2569,QI Y,HAN X,Qi Y and Han X co-authored a study on stage 1 hypertension,3\n2599,OMRON,ANSI/AAMI/ISO,Validated Omron's blood pressure monitoring devices,3\n2656,ACCORD STUDY GROUP,EVANS GW,Evans GW is a researcher involved in the ACCORD Study Group,3\n4452,DEMBOWSKI E,PROG CARDIOVASC DIS,Dembowski E co-authored guidelines published in Progress in Cardiovascular Diseases,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_1042d186d85ae4ad78e079370ee833627ec4f603c965e6a6a97b941975800fa9_v2"}